# Atlantic American Corp: financial statements, quarterly

AAME · Nasdaq · CIK 8177 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aame.md) · [Financials](/companies/aame/financials.md) · [Filings](/companies/aame/filings.md) · [Insiders](/companies/aame/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aame/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [46.3](/filings/0001140361-24-025855.md) | [49.2](/filings/0001140361-24-037251.md) | [44.6](/filings/0001140361-24-046143.md) | [46.7 d](/filings/0001140361-25-010239.md) | [47.0](/filings/0001140361-25-018588.md) | [47.7](/filings/0001140361-25-030558.md) | [44.5](/filings/0001140361-25-042275.md) | [48.9 d](/filings/0001140361-26-039951.md) | [50.1](/filings/0001140361-25-018588.md) | [55.3](/filings/0001140361-25-030558.md) | [53.8](/filings/0001140361-25-042275.md) | [51.3 d](/filings/0001140361-26-039951.md) |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | [0.8](/filings/0001140361-24-025855.md) | [0.8](/filings/0001140361-24-037251.md) | [0.9](/filings/0001140361-24-046143.md) | [0.9 d](/filings/0001140361-25-010239.md) | [0.9](/filings/0001140361-25-018588.md) | [0.9](/filings/0001140361-25-030558.md) | [0.9](/filings/0001140361-25-042275.md) | [0.8 d](/filings/0001140361-26-039951.md) | [0.8](/filings/0001140361-25-018588.md) | [0.8](/filings/0001140361-25-030558.md) | [0.8](/filings/0001140361-25-042275.md) | [0.8 d](/filings/0001140361-26-039951.md) |
| Income tax | $m | [(0.4)](/filings/0001140361-24-025855.md) | [0.5](/filings/0001140361-24-037251.md) | [0.4](/filings/0001140361-24-046143.md) | [(0.9) d](/filings/0001140361-25-010239.md) | [(0.5)](/filings/0001140361-25-018588.md) | [(0.2)](/filings/0001140361-25-030558.md) | [(0.5)](/filings/0001140361-25-042275.md) | [0.9 d](/filings/0001140361-26-039951.md) | [0.2](/filings/0001140361-25-018588.md) | [0.9](/filings/0001140361-25-030558.md) | [0.2](/filings/0001140361-25-042275.md) | [0.4 d](/filings/0001140361-26-039951.md) |
| Net income | $m | [(1.4)](/filings/0001140361-24-025855.md) | [1.7](/filings/0001140361-24-037251.md) | [1.8](/filings/0001140361-24-046143.md) | [(2.2) d](/filings/0001140361-25-010239.md) | [(2.0)](/filings/0001140361-25-018588.md) | [(0.7)](/filings/0001140361-25-030558.md) | [(2.0)](/filings/0001140361-25-042275.md) | [3.3 d](/filings/0001140361-26-039951.md) | [0.8](/filings/0001140361-25-018588.md) | [3.3](/filings/0001140361-25-030558.md) | [0.6](/filings/0001140361-25-042275.md) | [1.3 d](/filings/0001140361-26-039951.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001140361-24-025855.md) | [0.08](/filings/0001140361-24-037251.md) | [0.08](/filings/0001140361-24-046143.md) | not reported | [(0.10)](/filings/0001140361-25-018588.md) | [(0.04)](/filings/0001140361-25-030558.md) | [(0.10)](/filings/0001140361-25-042275.md) | not reported | [0.03](/filings/0001140361-25-018588.md) | [0.15](/filings/0001140361-25-030558.md) | [0.02](/filings/0001140361-25-042275.md) | not reported |
| Basic EPS | $ per share | [(0.08)](/filings/0001140361-24-025855.md) | [0.08](/filings/0001140361-24-037251.md) | [0.08](/filings/0001140361-24-046143.md) | not reported | [(0.10)](/filings/0001140361-25-018588.md) | [(0.04)](/filings/0001140361-25-030558.md) | [(0.10)](/filings/0001140361-25-042275.md) | not reported | [0.03](/filings/0001140361-25-018588.md) | [0.16](/filings/0001140361-25-030558.md) | [0.02](/filings/0001140361-25-042275.md) | not reported |

- Revenue: us-gaap:Revenues
- Operating income: not reported
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [13.5](/filings/0001140361-23-032398.md) | [24.2](/filings/0001140361-23-038586.md) | [23.9](/filings/0001140361-23-052979.md) | [28.3](/filings/0001140361-25-010239.md) | [21.2](/filings/0001140361-24-025855.md) | [21.2](/filings/0001140361-24-037251.md) | [23.0](/filings/0001140361-24-046143.md) | [35.6](/filings/0001140361-26-039951.md) | [35.9](/filings/0001140361-25-018588.md) | [46.4](/filings/0001140361-25-030558.md) | [34.4](/filings/0001140361-25-042275.md) | [43.6](/filings/0001140361-26-039951.md) |
| Total assets | $m | [354](/filings/0001140361-23-032398.md) | [373](/filings/0001140361-23-038586.md) | [362](/filings/0001140361-23-052979.md) | [379](/filings/0001140361-26-039951.md) | [366](/filings/0001140361-24-025855.md) | [386](/filings/0001140361-24-037251.md) | [387](/filings/0001140361-24-046143.md) | [382](/filings/0001140361-26-039951.md) | [388](/filings/0001140361-25-018588.md) | [429](/filings/0001140361-25-030558.md) | [431](/filings/0001140361-25-042275.md) | [434](/filings/0001140361-26-039951.md) |
| Total liabilities | $m | [249](/filings/0001140361-23-032398.md) | [269](/filings/0001140361-23-038586.md) | [263](/filings/0001140361-23-052979.md) | [274](/filings/0001140361-25-010239.md) | [263](/filings/0001140361-24-025855.md) | [285](/filings/0001140361-24-037251.md) | [281](/filings/0001140361-24-046143.md) | [271](/filings/0001140361-26-039951.md) | [286](/filings/0001140361-25-018588.md) | [323](/filings/0001140361-25-030558.md) | [321](/filings/0001140361-25-042275.md) | [313](/filings/0001140361-26-039951.md) |
| Shareholders' equity | $m | [104](/filings/0001140361-24-025855.md) | [103](/filings/0001140361-24-037251.md) | [98.7](/filings/0001140361-24-046143.md) | [106](/filings/0001140361-26-039951.md) | [103](/filings/0001140361-25-018588.md) | [101](/filings/0001140361-25-030558.md) | [106](/filings/0001140361-25-042275.md) | [111](/filings/0001140361-26-039951.md) | [102](/filings/0001140361-25-018588.md) | [106](/filings/0001140361-25-030558.md) | [109](/filings/0001140361-25-042275.md) | [121](/filings/0001140361-26-039951.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.6)](/filings/0001140361-24-025855.md) | [6.7 d](/filings/0001140361-24-037251.md) | [1.4 d](/filings/0001140361-24-046143.md) | [6.2 d](/filings/0001140361-25-010239.md) | [(5.3)](/filings/0001140361-25-018588.md) | [0.4 d](/filings/0001140361-25-030558.md) | [0.1 d](/filings/0001140361-25-042275.md) | [9.6 d](/filings/0001140361-26-039951.md) | [(0.7)](/filings/0001140361-25-018588.md) | [9.3 d](/filings/0001140361-25-030558.md) | [6.6 d](/filings/0001140361-25-042275.md) | [17.7 d](/filings/0001140361-26-039951.md) |
| Capital expenditure | $m | [0.1](/filings/0001140361-24-025855.md) | [0.0 d](/filings/0001140361-24-037251.md) | [0.0 d](/filings/0001140361-24-046143.md) | [0.0 d](/filings/0001140361-25-010239.md) | [0.0](/filings/0001140361-25-018588.md) | [0.1 d](/filings/0001140361-25-030558.md) | [0.0 d](/filings/0001140361-25-042275.md) | [0.1 d](/filings/0001140361-26-039951.md) | [0.3](/filings/0001140361-25-018588.md) | [0.2 d](/filings/0001140361-25-030558.md) | [0.0 d](/filings/0001140361-25-042275.md) | [0.0 d](/filings/0001140361-26-039951.md) |
| Dividends paid | $m | not reported | not reported | [0.4 d](/filings/0001140361-24-046143.md) | [0.0 d](/filings/0001140361-25-010239.md) | not reported | not reported | [0.0 d](/filings/0001140361-25-042275.md) | [0.0 d](/filings/0001140361-26-039951.md) | not reported | not reported | [0.0 d](/filings/0001140361-25-042275.md) | [0.0 d](/filings/0001140361-26-039951.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [21.8](/filings/0001140361-23-032398.md) | [20.4](/filings/0001140361-23-038586.md) | [20.4](/filings/0001140361-23-052979.md) | [20.4](/filings/0001140361-24-025855.md) | [21.8](/filings/0001140361-24-037251.md) | [21.8](/filings/0001140361-24-046143.md) | [20.4](/filings/0001140361-25-018588.md) | [20.4](/filings/0001140361-25-030558.md) | [20.4](/filings/0001140361-25-042275.md) | [20.4](/filings/0001140361-25-018588.md) | [21.8](/filings/0001140361-25-030558.md) | [20.4](/filings/0001140361-25-042275.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 20,397,228 at 2026-10-01, from the cover of the [10-K/A filed 2026-10-19](/filings/0001140361-26-039951.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:17 ET. No prices; not investment advice.